After capital-markets day flop, Novo strikes licensing deal that sends a Swedish company’s stock soaring

Just days after a capital-markets day left investors wondering what’s next for Novo Nordisk, the Danish drug giant struck a licensing deal worth over $1 billion.

Source:MarketWatch
Disclaimer:Please read market information rationally and stay aware of investment risks. All content on this site is for informational purposes only and does not constitute investment advice.